Pipeline

  Description Tropism Payload(s) Stage of Dev Ownership

GVB2030

Oncolytic vaccinia virus in combination of anti-PD-1 against bladder cancer

Tumor, tumor associated vasculature

Cytokines

Preclinical: cell and animal data

1/3rd ownership by GVB

GVB2020

In vivo transduction vector for CAR- or TCR-T cells (oncology & immunology)

T-Cells

Cytokines and CAR- or TCR-construct

Preclinical: validated in cells

100% owned by GVB

GVB2010

Oncolytic vaccinia virus for systematic delivery

Tumor, Tumor associated vasculature

Immunogenic cell death, checkpoint inhibitor, fusogenic

Preclinical: validated in animal models

100% owned by GVB

Genvira has several other in-houseand partnered assets with IP (cancer vaccine PCT) that are being developed